Janssen Prods Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PRODS, and what generic alternatives to JANSSEN PRODS drugs are available?
JANSSEN PRODS has eight approved drugs.
There are twenty-three US patents protecting JANSSEN PRODS drugs.
There are seven hundred and eighty-seven patent family members on JANSSEN PRODS drugs in sixty-four countries and two hundred and forty-eight supplementary protection certificates in nineteen countries.
Drugs and US Patents for Janssen Prods
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 9,623,022 | ⤷ Subscribe | ⤷ Subscribe | ||||
Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 8,741,926 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-001 | Jun 23, 2006 | DISCN | Yes | No | 7,700,645*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-004 | Dec 18, 2008 | RX | Yes | No | 7,700,645*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-003 | Oct 21, 2008 | DISCN | Yes | No | 8,518,987*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | 9,296,769 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Janssen Prods | YONDELIS | trabectedin | POWDER;INTRAVENOUS | 207953-001 | Oct 23, 2015 | RX | Yes | Yes | 8,895,557*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Prods
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Prods | PREZCOBIX | cobicistat; darunavir | TABLET;ORAL | 205395-001 | Jan 29, 2015 | RE43802*PED | ⤷ Subscribe |
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-003 | Oct 21, 2008 | 6,248,775*PED | ⤷ Subscribe |
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-002 | Feb 25, 2008 | 8,597,876*PED | ⤷ Subscribe |
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-003 | Oct 21, 2008 | 8,518,987*PED | ⤷ Subscribe |
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-006 | Nov 9, 2012 | RE43596*PED | ⤷ Subscribe |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 7,803,788 | ⤷ Subscribe |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 9,889,115 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
International Patents for Janssen Prods Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20161502 | ⤷ Subscribe |
Japan | 2011236221 | ⤷ Subscribe |
Montenegro | 02582 | ⤷ Subscribe |
Portugal | 1713823 | ⤷ Subscribe |
Taiwan | I315199 | ⤷ Subscribe |
Taiwan | I444367 | ⤷ Subscribe |
Ukraine | 92467 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Prods Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1663240 | 122015000088 | Germany | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
1632232 | 122016000111 | Germany | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
2487163 | 1790002-8 | Sweden | ⤷ Subscribe | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/15/1025, 2015-07-15 |
2932970 | 1890039-9 | Sweden | ⤷ Subscribe | PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518 |
2487162 | CA 2017 00002 | Denmark | ⤷ Subscribe | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF OG DARUNAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, ISAER DARUNAVIRETHANOLAT; REG. NO/DATE: EU/1/14/967/001 20141121 |
2049506 | PA2015040 | Lithuania | ⤷ Subscribe | PRODUCT NAME: COBICISTATUM; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524 |
2487166 | PA2016038,C2487166 | Lithuania | ⤷ Subscribe | PRODUCT NAME: KOBICISTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA IR TENOFOVIRO ALAFENAMIDAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC TENOFOVIRO ALAFENAMIDO FUMARATAS; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.